MOONLAKE IMMUNOTHERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.26 USD | +6.32% |
|
+6.52% | -25.05% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 409.3 | 3,620 | 2,846 | - | - |
| Enterprise Value (EV) 1 | 337.2 | 3,109 | 2,337 | 2,410 | 2,452 |
| P/E ratio | -6.18 x | -82.7 x | -41.4 x | -27.7 x | -20 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -6.09 x | -57.5 x | -29.3 x | -20 x | -14.6 x |
| EV / FCF | -6.03 x | -72.2 x | -31.3 x | -18.1 x | -11 x |
| FCF Yield | -16.6% | -1.39% | -3.19% | -5.52% | -9.13% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 38,978 | 59,941 | 62,875 | - | - |
| Reference price 2 | 10.50 | 60.39 | 45.26 | 45.26 | 45.26 |
| Announcement Date | 3/20/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | -55.39 | -54.11 | -79.85 | -120.4 | -168.2 |
| EBIT 1 | -65.06 | -54.12 | -90.43 | -129.4 | -185 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -64.47 | -43.98 | -81.7 | -127.3 | -184.6 |
| Net income 1 | -49.97 | -36.01 | -70.57 | -100.5 | -144.5 |
| Net margin | - | - | - | - | - |
| EPS 2 | -1.700 | -0.7300 | -1.093 | -1.632 | -2.262 |
| Free Cash Flow 1 | -55.91 | -43.06 | -74.63 | -133 | -223.9 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/20/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | -15.03 | -16.3 | -18.82 | -23.79 | -29.03 | - |
| EBIT 1 | - | -17.65 | -14.77 | -16.7 | -12.93 | -13.19 | -12.98 | -15.03 | -16.21 | -20.24 | -24.18 | -28.67 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -17.41 | -14.73 | -16.46 | -12.21 | -12.34 | -11.59 | -7.843 | -13.91 | -18.48 | -23.33 | -28.65 | - |
| Net income 1 | -2.704 | -17.42 | -10.11 | -17.11 | -9.005 | -10.14 | -11.62 | -7.437 | -11.51 | -14.95 | -19.39 | -24.08 | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | -0.3400 | -0.2700 | -0.4300 | -0.2300 | -0.2300 | -0.1800 | -0.1200 | -0.1975 | -0.2547 | -0.3095 | -0.3870 | -0.7500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/16/22 | 8/12/22 | 11/14/22 | 3/20/23 | 5/11/23 | 8/10/23 | 11/14/23 | 2/29/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 72.1 | 511 | 509 | 436 | 394 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | -55.9 | -43.1 | -74.6 | -133 | -224 |
| ROE (net income / shareholders' equity) | - | -7.01% | -14.8% | -31% | -69.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | 0.02 | 0.28 | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/20/23 | 2/29/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
45.26
USD
Average target price
73.38
USD
Spread / Average Target
+62.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.05% | 2.85B | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- MLTX Stock
- Financials MoonLake Immunotherapeutics
